| [1] |
Burra P, Rodriguez-Castro KI, Marchini F, et al. Hepatitis C virus infection in end-stage renal disease and kidney transplantation. [J] Transpl Int, 2014, 27(9):877-891. DOI: 10.1111/tri.12360.
|
| [2] |
Morales JM, Fabrizi F. Hepatitis C and its impact on renal transplantation. [J] Nat Rev Nephrol, 2015, 11(3):172-182. DOI: 10.1038/nrneph.2015.5.
|
| [3] |
Zaltron S, Spinetti A, Biasi L, et al. Chronic HCV infection: epidemiological and clinical relevance [J]. BMC Infect Dis, 2012, 12 (Suppl 2):S2. DOI: 10.1186/1471-2334-12-S2-S2.
|
| [4] |
AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus[J]. Hepatology, 2015, 62(3):932-954. DOI: 10.1002/hep.27950.
|
| [5] |
European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015 [J]. J Hepatol, 2015, 63(1):199-236. DOI: 10.1016/j.jhep.2015.03.025.
|
| [6] |
Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation [J]. Kidney Int, 1997, 51(4):981-999. doi: 10.1038/ki.1997.139
|
| [7] |
Roth D. Hepatitis C virus: the nephrologist's view[J]. Am J Kidney Dis, 1995, 25(1):3-16. doi: 10.1016/0272-6386(95)90617-7
|
| [8] |
Dominguez-Gil B, Morales JM. Transplantation in the patient with hepatitis C [J]. Transpl Int, 2009, 22(12):1117-1131. DOI: 10.1111/j.1432-2277.2009.00926.x.
|
| [9] |
EBPG (European Expert Group on Renal Transplantation), European Renal Association (ERA-EDTA); European Society for Organ Transplantation (ESOT). European best practice guidelines for renal transplantation (part 1) [J].Nephrol Dial Transplant, 2000, 15 Suppl 7:1-85.
|
| [10] |
Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. [J] Kidney Int Suppl, 2008, (109):S1-S99. DOI: 10.1038/ki.2008.81.
|
| [11] |
Huang CF, Yang JF, Dai CY, et al. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C[J]. J Infect Dis, 2010, 201(5):751-759. DOI: 10.1086/650470.
|
| [12] |
Webster DP, Klenerman P, Dusheiko GM. Hepatitis C [J]. Lancet, 2015, 385(9973):1124-1135. DOI: 10.1016/S0140-6736(14)62401-6.
|
| [13] |
Fabrizi F, Penatti A, Messa P, et al. Treatment of hepatitis C after kidney transplant: a pooled analysis of observational studies[J]. J Med Virol, 2014, 86(6):933-940. DOI: 10.1002/jmv.23919.
|
| [14] |
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014 [J]. J Hepatol, 2014, 61(2):373-395. DOI: 10.1016/j.jhep.2014.05.001.
|
| [15] |
Sovaldi (sofosbuvir) tablets: US prescribing information[EB/OL].[2015-01-28]. http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf
|
| [16] |
Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial[J]. Lancet, 2014, 383(9916):515-523. DOI: 10.1016/S0140-6736(13)62121-2.
|
| [17] |
Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options [J]. N Engl J Med, 2013, 368(20):1867-1877. DOI: 10.1056/NEJMoa1214854.
|
| [18] |
Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV[J]. N Engl J Med, 2014, 370(21):1983-1992. DOI: 10.1056/NEJMoa1402338.
|
WeChat Subscription Account
Wechat Service Account
Supported by:
Beijing Renhe Information Technology Co. Ltd
DownLoad: